OncoSil Medical (ASX:OSL) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical Change In Receivables?

OncoSil Medical's change in receivables for the quarter that ended in Dec. 2024 was A$0.00 Mil. It means OncoSil Medical's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

OncoSil Medical's change in receivables for the fiscal year that ended in Jun. 2024 was A$0.00 Mil. It means OncoSil Medical's Accounts Receivable stayed the same from Jun. 2023 to Jun. 2024 .

OncoSil Medical's Accounts Receivable for the quarter that ended in Dec. 2024 was A$2.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. OncoSil Medical's Days Sales Outstanding for the six months ended in Dec. 2024 was 800.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. OncoSil Medical's liquidation value for the six months ended in Dec. 2024 was A$7.04 Mil.

OncoSil Medical Change In Receivables Historical Data

The historical data trend for OncoSil Medical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSil Medical Change In Receivables Chart

OncoSil Medical Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

Get a 7-Day Free Trial

OncoSil Medical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

OncoSil Medical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

OncoSil Medical (ASX:OSL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

OncoSil Medical's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.014	/	0.459	*	91
=	800.77

2. In Ben Graham's calculation of liquidation value, OncoSil Medical's accounts receivable are only considered to be worth 75% of book value:

OncoSil Medical's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.466	-	2.94	+	0.75 * 2.014	+	0.5 * 0
=	7.04

OncoSil Medical Change In Receivables Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSil Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113

Website

https://www.oncosil.com

OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.

OncoSil Medical Headlines

No Headlines